RSNA 2025: Philips Expands Availability of LumiGuide 3D Device Guidance

Philips announced expanded commercial availability of LumiGuide 3D Device Guidance, which the company markets as the world’s first real-time, artificial intelligence (AI)-enabled, light-based 3D navigation solution for image-guided therapy.

Philips said LumiGuide is a breakthrough in radiation-free navigation. Physicians can use it to visualize and guide devices in the body using light instead of continuous X-ray. The news was announced at this week’s RSNA 2025 meeting.

LumiGuide integrated with Azurion, Philips’ image-guided therapy platform that was designed to drive procedural innovation. LumiGuide joins a suite of intelligent, AI-enabled supportive and therapeutic devices on the Azurion platform.

“I have done over 160 fenestrated and branched aortic procedures with LumiGuide and have found that the system improves efficiency, reduces the procedure time, and reduces time on the fluoroscopy pedal to near zero,” said Adam W. Beck, MD, Professor and Director, Division of Vascular Surgery & Endovascular Therapy, University of Alabama at Birmingham.

LumiGuide is powered by Philips Fiber Optic RealShape (FORS) technology. The company said it’s the first solution to visualize shape and position of LumiGuide wires and compatible endovascular catheters inside the body in real time and in 3D without X-ray. By reflecting light along an optical fiber integrated into the guidewire, LumiGuide shows high-resolution, full-color images from any angle, giving physicians instant orientation during complex endovascular procedures.

LumiGuide uses AI to quickly and accurately align any image with the patient’s anatomy. This technology allows clinicians to navigate with precision, while significantly reducing radiation exposure for both patients and clinical staff. Using this advanced technology, complex cases such as aortic repair procedures can be performed 37% faster and with up to 56% DAP reduction, Philips said.

Following a successful limited market release in late 2023, LumiGuide will be commercially available from January 2026 in key European markets and the United States.

“Moving LumiGuide from limited to full commercial availability is an important milestone in expanding access to advanced image-guided therapy,” said Stacey Beske, Business Leader Image-Guided Therapy Devices at Philips.

“By bringing this light-based navigation technology to more hospitals, we’re helping clinicians treat complex vascular disease with precision and safety, while reducing radiation risk for patients and teams in the lab,” added Atul Gupta, MD, Chief Medical Officer Diagnosis & Treatment at Philips.